Remission of severe aphthous stomatitis of celiac disease with etanercept

Clinical and Molecular Allergy

Guha Krishnaswamy⁴  John Litchfield¹  George Youngberg²  Hana Saleh³  Hiren Patel³  Adey Hasan³ 

[1] The Department of Internal Medicine, East Tennessee State University, Johnson City, TN, USA;Department of Pathology, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA;Division of Allergy, Asthma and Immunology, East Tennessee State University, PO Box 70622, Johnson City, TN, USA;Department of Medicine, Quillen College of Medicine, Johnson City, TN 37614-0622, USA

关键词: Tumor necrosis factor;    Etanercept;    Aphthous stomatitis;    Gluten-sensitivity;    Celiac disease;   

Others  :  790419
DOI  :  10.1186/1476-7961-11-6

 received in 2013-01-02, accepted in 2013-12-13,  发布年份 2013

【 摘 要 】

Celiac disease is a common autoimmune disease triggered by gluten-containing foods (wheat, barley and rye) in genetically predisposed individuals. We present a patient with celiac disease complicated by severe aphthous stomatitis resulting in impairing swallowing, chewing and speaking. This led to weight loss, psychosocial problems as well as inability to perform her work. A variety of topical and systemic medications used resulted in either no improvement or only partial alleviation of the patient’s symptoms. After informed consent, etanercept was initiated and resulted in complete remission of aphthous stomatitis, decrease in arthralgia and fatigue and considerable improvement in her quality of life. The use of newer biological agents for selected and severe manifestations of celiac disease may lead to improved morbidity in these patients, but more studies are needed to determine long-term efficacy as well as safety of these drugs in the mucosal and/or systemic complications of this disease.

【 授权许可】

   
2013 Hasan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Gujral N, Freeman HJ, Thomson AB: Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol 2012, 18(42):6036-6059.
• [2]Rashid M, Zarkadas M, Anca A, Limeback H: Oral manifestations of celiac disease: a clinical guide for dentists. J Mich Dent Assoc 2011, 93(10):42-46.
• [3]Kagnoff MF: Celiac disease. A gastrointestinal disease with environmental, genetic, and immunologic components. Gastroenterol Clin North Am 1992, 21(2):405-425.
• [4]Schuppan D: Current concepts of celiac disease pathogenesis. Gastroenterology 2000, 119(1):234-242.
• [5]Kupfer SS, Jabri B: Pathophysiology of celiac disease. Gastrointest Endosc Clin N Am 2012, 22(4):639-660.
• [6]McCabe MA, Toughill EH, Parkhill AM, Bossett MS, Jevic MS, Nye ML: Celiac disease: a medical puzzle. Am J Nurs 2012, 112(10):34-44.
• [7]Westerberg DP, Gill JM, Dave B, DiPrinzio MJ, Quisel A, Foy A: New strategies for diagnosis and management of celiac disease. J Am Osteopath Assoc 2006, 106(3):145-151.
• [8]Medina M, De PG, Ribes-Koninckx C, Calabuig M, Sanz Y: Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. J Inflamm (Lond) 2008, 5:19. BioMed Central Full Text
• [9]Bucci P, Carile F, Sangianantoni A, D’Angio F, Santarelli A, Lo ML: Oral aphthous ulcers and dental enamel defects in children with coeliac disease. Acta Paediatr 2006, 95(2):203-207.
• [10]Ferguson MM, Wray D, Carmichael HA, Russell RI, Lee FD: Coeliac disease associated with recurrent aphthae. Gut 1980, 21(3):223-226.
• [11]Ferguson R, Basu MJ, Asquith P, Cooke WT: Proceedings: recurrent aphthous ulceration and its association with coeliac disease. Gut 1975, 16(5):393.
• [12]MacPhail L: Topical and systemic therapy for recurrent aphthous stomatitis. Semin Cutan Med Surg 1997, 16(4):301-307.
• [13]Eguia-del VA, Martinez-Conde-Llamosas R, Lopez-Vicente J, Uribarri-Etxebarria A, Aguirre-Urizar JM: Salivary levels of Tumour Necrosis Factor-alpha in patients with recurrent aphthous stomatitis. Med Oral Patol Oral Cir Bucal 2011, 16(1):e33-e36.
• [14]Thornhill MH, Baccaglini L, Theaker E, Pemberton MN: A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol 2007, 143(4):463-470.
• [15]Preshaw PM, Grainger P, Bradshaw MH, Mohammad AR, Powala CV, Nolan A: Subantimicrobial dose doxycycline in the treatment of recurrent oral aphthous ulceration: a pilot study. J Oral Pathol Med 2007, 36(4):236-240.
• [16]Sharquie KE, Najim RA, Al-Hayani RK, Al-Nuaimy AA, Maroof DM: The therapeutic and prophylactic role of oral zinc sulfate in management of recurrent aphthous stomatitis (ras) in comparison with dapsone. Saudi Med J 2008, 29(5):734-738.
• [17]Davatchi F, Sadeghi AB, Tehrani BA, Shahram F, Nadji A, Shams H, Chams-Davatchi C: Colchicine versus placebo in Behcet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009, 19(5):542-549.
• [18]de Abreu MA, Hirata CH, Pimentel DR, Weckx LL: Treatment of recurrent aphthous stomatitis with clofazimine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 108(5):714-721.
• [19]Femiano F, Buonaiuto C, Gombos F, Lanza A, Cirillo N: Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 109(3):402-407.
• [20]Lynde CB, Bruce AJ, Rogers RS III: Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 2009, 145(3):273-276.
• [21]Paterson DL, Georghiou PR, Allworth AM, Kemp RJ: Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995, 20(2):250-254.
• [22]Evereklioglu C: Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005, 50(4):297-350.
• [23]Zouboulis CC: Extended venous thrombosis in Adamantiades-Behcet’s disease. Eur J Dermatol 2004, 14(4):268-271.
• [24]Haugeberg G, Velken M, Johnsen V: Successful treatment of genital ulcers with infliximab in Behcet’s disease. Ann Rheum Dis 2004, 63(6):744-745.
• [25]Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H: Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol 2005, 32(1):98-105.
• [26]Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998, 134(8):1010-1016.
• [27]Jurge S, Kuffer R, Scully C, Porter SR: Mucosal disease series. Number VI. Recurrent aphthous stomatitis. Oral Dis 2006, 12(1):1-21.
• [28]O’Neill ID: Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med 2008, 37(10):575-581.
• [29]Nowak M, Dziechciarz P, Dwilewicz-Trojaczek J: The frequency of coeliac disease occurrence in patients with recurrent aphthous stomatitis (RAS)-preliminary report. Wiad Lek 2002, 55(9–10):542-546.
• [30]Lewkowicz N, Lewkowicz P, Dzitko K, Kur B, Tarkowski M, Kurnatowska A, Tchorzewski H: Dysfunction of CD4+CD25high T regulatory cells in patients with recurrent aphthous stomatitis. J Oral Pathol Med 2008, 37(8):454-461.
• [31]Altenburg A, Zouboulis CC: Current concepts in the treatment of recurrent aphthous stomatitis. Skin Therapy Lett 2008, 13(7):1-4.
• [32]O’Neill ID: Efficacy of tumour necrosis factor-alpha antagonists in aphthous ulceration: review of published individual patient data. J Eur Acad Dermatol Venereol 2012, 26(2):231-235.
• [33]Sanchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ortego-Centeno N: Recalcitrant, recurrent aphthous stomatitis successfully treated with adalimumab. J Eur Acad Dermatol Venereol 2009, 23(2):206.
• [34]Ting PT, Koo JY: Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol 2006, 45(6):689-692.
• [35]Peppel K, Crawford D, Beutler B: A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991, 174(6):1483-1489.
• [36]Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O’Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE: Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 2007, 179(3):1872-1883.
• [37]Mehta PA, Svahn J, Davies SM, Pang Q, Harris R, Ghezzi P, Lanza T, Ferretti E, Barabino P, Mueller R, Dufour C: Etanercept treatment in Fanconi anaemia; combined US and Italian experience. Br J Haematol 2012, 158(6):809-811.
• [38]Sokumbi O, Wetter DA, Makol A, Warrington KJ: Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin Proc 2012, 87(8):739-745.
• [39]Spadaro A, Lubrano E, Ferrara N, Scarpa R: Etanercept in psoriatic arthritis. J Rheumatol Suppl 2012, 89:74-76.